Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PMI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPicard Medical restructures warrants, slashing exercise price 87% and adding 43% more shares
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Company exchanged 7M warrants at $2.675 for 10M new warrants at $0.35, increasing potential dilution by 43% while making exercise far more likely at the drastically lower price
Item 1.01 verify on EDGAR → -
medium
Removed forced exercise provision that would have converted warrants to equity when stock doubled and stayed elevated for 20 days, allowing warrants to remain outstanding indefinitely
Item 1.01 verify on EDGAR → -
medium
Eliminated anti-dilution ratchet that previously lowered exercise price and increased share count if company issued cheap stock, trading future protection for upfront lower price
Item 1.01 verify on EDGAR → -
medium
New warrants allow cashless exercise when shares aren't registered, meaning company may not receive the $3.5M that would come from cash exercise of all warrants
Item 1.01 verify on EDGAR → -
medium
Exchange conditioned on closing pending Form S-1 registered offering, suggesting broader capital restructuring tied to new equity raise
Item 1.01 verify on EDGAR →
Summary
Picard Medical dramatically restructured its outstanding warrants in a deal that significantly increases potential shareholder dilution. The company exchanged 7 million warrants with a $2.675 exercise price for 10 million new warrants at just $0.35 per share—an 87% reduction that makes exercise far more economically attractive to the holder.
This increases potential dilution by 43% while removing key protections the company previously had, including the ability to force exercise during strong stock performance and anti-dilution ratchets that would have protected against future cheap stock issuances. Retail investors should understand this as a capital structure reset that favors the warrant holder at the expense of existing shareholders.
The drastically lower exercise price means these warrants are much more likely to be exercised, potentially adding 10 million shares to the float. The exchange is tied to closing a pending registered offering, suggesting the company needed to restructure these warrants as part of raising new capital. Watch whether the S-1 offering closes and at what terms, as this will determine whether the warrant exchange becomes effective. Also monitor if the warrant holder begins exercising at the new $0.35 price, which would immediately dilute existing shareholders and could pressure the stock price.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the New Warrants eliminate certain provisions contained in the Existing Warrants, including (i) the forced exercise provisions, which permitted the Company to require the Holder to exercise the Existing Warrants upon the occurrence of a "Forced Exercise Trigger" (defined as the closing sale price exceeding 200% of the exercise price on each of twenty consecutive trading days)
The company removed its ability to force warrant exercise when the stock price doubled and stayed elevated for 20 days. This eliminates a mechanism that would have converted warrants to equity during strong performance, meaning the warrants now remain outstanding indefinitely (up to 5 years) regardless of stock price appreciation.
Added in current filing · verify on EDGAR →
The New Warrants may be exercised by means of a “cashless exercise” at any time when there is no effective registration statement available for the resale of the New Warrant Shares.
The warrant holder can exercise without paying cash by receiving fewer shares based on a formula, whenever the shares aren't registered for resale. This means the company may not receive the $3.5 million in proceeds that would come from cash exercise of all 10 million warrants.
Added in current filing · verify on EDGAR →
The Exchange is conditioned upon the closing of the Company’s current registered offering on Form S-1 (File No. 333-295333) pursuant to its terms.
The warrant exchange only happens if the company completes its pending registered stock offering. This suggests the exchange is part of a broader capital restructuring tied to raising new equity capital.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Picard Medical disclosed an unregistered sale of equity securities via exchange agreement and new warrants.
Added in current filing · verify on EDGAR →
Item | 3.02 | Unregistered | Sale of Equity Securities.
The information contained above in Item 1.01 regarding the Exchange Agreement and the New Warrants is hereby incorporated by reference into this Item 3.02.
The company disclosed an unregistered sale of equity securities through an Exchange Agreement and issuance of New Warrants. The filing references Item 1.01 for details, but that section is not included in the provided text, limiting visibility into the transaction's terms, size, and parties involved.
Event · Item 9.01 — Financial Statements and Exhibits
Picard Medical issued warrants and entered into a warrant exchange agreement with an investor on May 5, 2026.
Added in current filing · verify on EDGAR →
Warrant Issuance and Exchange Agreement, dated as of May 5, 2026, by and between Picard Medical, Inc. and the investor signatory thereto.
Picard Medical entered into a warrant issuance and exchange agreement with an investor on May 5, 2026. The agreement involves the issuance of warrants to purchase common stock. The specific terms, number of shares, exercise price, and identity of the investor are not disclosed in this 8-K filing itself but would be detailed in the attached exhibits.
Added in current filing · verify on EDGAR →
Warrant to Purchase Shares of Common Stock, dated May 5, 2026
The company issued a warrant allowing the holder to purchase shares of Picard Medical common stock. Warrants are dilutive securities that give investors the right to buy stock at a predetermined price, potentially increasing share count and diluting existing shareholders if exercised.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify